UK Biobank

has recruited and follows roughly 500,000 UK participants, with its linked biospecimens and health data underpinning a continuous stream of published genomic and epidemiological research across cardiovascular, oncology and neurological disease.

Country: United Kingdom

Research Institute ~500,000-participant population cohort

Coverage

	CN	EU	IN	US
diagnostics-medtech	✓	✓	✓	✓

Regulatorsfdaemanmpa

Verifiable facts

Fact	Value	Source
Founded	November 2003	ukbiobank.ac.uk
Research focus	large-scale biomedical research into the prevention, diagnosis and treatment of diseases	pubmed.ncbi.nlm.nih.gov
Facility	imaging sites in Reading, Bristol, Cheadle, and Newcastle; facility in Stockport; new facility at Manchester Science Park	ukbiobank.ac.uk
Grant	£127.6 million from UKRI Infrastructure Fund; multiple core and project-specific grants from public and private funders	ukbiobank.ac.uk
Publications	over 18,000 peer-reviewed scientific papers	ukbiobank.ac.uk
Principal staff	Professor Sir Rory Collins (CEO and Principal Investigator), Dr Naomi Allen (Chief Scientist), Dr Mark Effingham (Deputy CEO), Gareth Gregory (CFO)	ukbiobank.ac.uk
Headcount	315 (as of September 2025)	findthatcharity.uk · ukbiobank.ac.uk

Independent sources: findthatcharity.uk · pubmed.ncbi.nlm.nih.gov

Technologies

Name	Cluster	Risk
Biobanks of human & population samples	diagnostics-medtech	Low	→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.